April 2013 in “The FASEB Journal” In this study, dutasteride, but not finasteride, reduced high-grade PIN lesions more effectively in C57xFVB TRAMP mice, although both drugs increased the incidence of poorly differentiated prostate cancer.
1 citations
,
November 2010 in “Anticancer Research” This study concluded that both finasteride and dutasteride therapies significantly increased chromogranin A serum levels in men with benign prostatic hyperplasia, suggesting an activation of neuroendocrine differentiation.
386 citations
,
April 2006 in “PubMed” This review discusses the prevalence and treatment of benign prostatic hyperplasia and reports no new findings; it emphasizes considering side effects and comorbidities in therapy choices.
20 citations
,
January 2004 in “PubMed” This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.